about
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerEfficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study.Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyrCabozantinib in progressive medullary thyroid cancer.A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Motesanib diphosphate in progressive differentiated thyroid cancer.BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerPhase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe impact of age and gender on papillary thyroid cancer survival.Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis.Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancerThe noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentEvolving approaches to patients with advanced differentiated thyroid cancerPostoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment.Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.Molecularly targeted therapies for thyroid cancers.Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy.Tyrosine kinase inhibitors and the thyroid.Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma.Cytotoxic chemotherapy for differentiated thyroid carcinoma.Targeted therapy of thyroid cancer.Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer.Targeted therapies for thyroid tumors.The safety of incretin-based therapies--review of the scientific evidence.Approach to the patient with advanced differentiated thyroid cancer.The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer.Unique characteristics and outcomes of patients diagnosed with both primary thyroid and primary renal cell carcinoma.Sucralfate causes malabsorption of L-thyroxine.
P50
Q28262641-19343293-AC19-48DF-B441-6FA0AA5C7FECQ30367068-77087E77-86D1-47F0-A3A8-415B7689671FQ33465649-1E79CCBF-E8E4-42CB-8AB5-8C4887380A2FQ33570297-690B1A70-498E-407E-BAFA-5FE60A3EF7F8Q33577870-81D60CF5-405B-4ABB-8E41-A3506CED206EQ33602360-16BDCE8F-CB5B-4AD0-9897-02E571AC4B78Q33682381-48A753EE-EDF9-46B1-8F16-F6716DBAF6E4Q33842300-7C1478EA-511E-4BD4-B755-5D8B505E5364Q33990855-6D49CD9F-30F0-4381-B662-A4C04A0B2741Q34185084-B4F5F8F7-B6E9-4297-B4B8-3F362F4D6F17Q34188774-4975BB1F-96AB-4BDF-9CE8-76044B898D97Q34330748-D14C4662-84D8-4CB6-8F79-199DE46FD5FDQ34791480-9958D279-580B-400D-8594-9A9895BD6C1BQ34919430-C498F5E4-02AD-44AB-B9A7-82A0F4F87D4CQ34989774-C66660ED-A4A1-409B-9188-2438C6AB665AQ35103694-A24D744D-490E-48FD-8821-4941391334C3Q35195766-D18F5B9D-24D2-4826-9485-A89CD4975347Q36069888-1D5612DF-0AE3-4BEB-9BA8-1949E09ECC59Q36108073-6F68921E-29CB-4E89-8205-AF1357C942A6Q36467394-2B0BF3AF-F358-425A-B9F8-6C461DCB590AQ36508942-DF7427C9-F1DA-4D6B-8274-C735C015D426Q36716739-DB7447EC-B116-467B-8268-47C0DC46D329Q36864736-FF3B27F8-D289-47DA-A4BD-A165F1295E09Q37350130-05E503A7-52AE-4DFD-82B5-2ED7D200DF59Q37405723-8C0A2B1B-CDB0-45E2-9943-9D73A67BF0F8Q37527371-07C781A5-C59E-41F6-BD98-EAA761C5FFECQ37626641-56942BE5-F765-408F-978F-D6142408CB1CQ37639652-A029C8B5-19A1-427E-9F1A-00E6E0B619BCQ37667684-F1CE3237-9EFE-45BB-B455-7EFC2D4A449FQ37671104-0C0D1D18-C8E0-426F-80E5-31C75D296B6EQ37746327-20ACB95F-DBE7-4235-8D45-19046A4B8FBBQ37752840-A418399F-A00B-4004-AC35-AC0F62822B1CQ37782505-FDD93ED5-F8AE-48C4-ACFB-2181337FF0A0Q37845613-43AB18BD-91DF-4894-8ECB-EC746CB4688EQ37860132-6CEFDF00-584E-4C73-ADA1-32674F802CA0Q37898348-49916BAD-7480-4620-BFF5-7E637AF4A0E5Q37926291-AE10F706-ECAD-49AF-940C-FD28007344E4Q38084057-C9CBB774-3120-4C8F-A901-2B9B852F597BQ38299244-189BDA4A-FD68-41FF-A3F2-D97F3CCDA14EQ38307668-62C82C5C-C447-45BF-8751-B865014CDE37
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Steven I. Sherman
@ast
Steven I. Sherman
@en
Steven I. Sherman
@es
Steven I. Sherman
@nl
Steven I. Sherman
@sl
type
label
Steven I. Sherman
@ast
Steven I. Sherman
@en
Steven I. Sherman
@es
Steven I. Sherman
@nl
Steven I. Sherman
@sl
altLabel
Steven I Sherman
@en
Steven Sherman
@en
prefLabel
Steven I. Sherman
@ast
Steven I. Sherman
@en
Steven I. Sherman
@es
Steven I. Sherman
@nl
Steven I. Sherman
@sl
P106
P1153
7402440489
P21
P31
P496
0000-0002-3079-5153